Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

When the fracture risk is low, bisphosphonates and raloxifene should be stopped, and lifestyle and adequate calcium and vitamin D intake should be continued.

Source: A lifelong fracture prevention strategy is indicated from the start of the first treatment. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena

Study design awaiting verification · Archives of Osteoporosis · 2024

Original publication title

The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena

J. P. van den Bergh; P. Geusens; N. M. Appelman-Dijkstra; H. J. G. van den Broek; P. J. M. Elders; G. de Klerk; M. van Oostwaard; H. C. Willems; M. C. Zillikens; W. F. Lems

© The Author(s) 2024

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.

An extract from the source publication. Read it in context.

At a glance

Abstract: What background does the paper provide?

In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions.

Source: Background

Abstract: What methods does the paper describe?

A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient’s organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline.

Source: Methods

Abstract: Results

Novel recommendations in our guideline are as follows:

: In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA.

: Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk;

: Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA);

: Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk;

: A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.

Source: Results Source: Results Source: Results Source: Results Source: Results Source: Results

Abstract: Conclusion

In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.

Source: Conclusion
Authors’ abstract

Background

In 2018, a grant was provided for an evidence-based guideline on osteoporosis and fracture prevention based on 10 clinically relevant questions.

Methods

A multidisciplinary working group was formed with delegates from Dutch scientific and professional societies, including representatives from the patient’s organization and the Dutch Institute for Medical Knowledge. The purpose was to obtain a broad consensus among all participating societies to facilitate the implementation of the updated guideline.

Results

Novel recommendations in our guideline are as follows:

: In patients with an indication for DXA of the lumbar spine and hips, there is also an indication for VFA.

: Directly starting with anabolic drugs (teriparatide or romosozumab) in patients with a very high fracture risk;

: Directly starting with zoledronic acid in patients 75 years and over with a hip fracture (independent of DXA);

: Directly starting with parenteral drugs (denosumab, teriparatide, zoledronic acid) in glucocorticoid-induced osteoporosis with very high fracture risk;

: A lifelong fracture risk management, including lifestyle, is indicated from the start of the first treatment.

Conclusion

In our new multidisciplinary guideline osteoporosis and fracture prevention, we developed 5 “relatively new statements” that are all a crucial step forward in the optimization of diagnosis and treatment for fracture prevention. We also developed 5 flowcharts, and we suppose that this may be helpful for individual doctors and their patients in daily practice and may facilitate implementation.

Publication and source details

Original title: The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena

J. P. van den Bergh; P. Geusens; N. M. Appelman-Dijkstra; H. J. G. van den Broek; P. J. M. Elders; G. de Klerk; M. van Oostwaard; H. C. Willems; M. C. Zillikens; W. F. Lems

Archives of Osteoporosis · 2024

© The Author(s) 20242024https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:25:59.653005+00:00

DOI: 10.1007/s11657-024-01378-3 · PMC10987374